Abstract
Brentuximab vedotin (BV) monotherapy has significant clinical efficacy against relapsed anaplastic large cell lymphoma. While BV monotherapy re-administration and extended duration of treatment show therapeutic potential, particularly in patients ineligible for autologous hematopoietic stem cell transplantation or conventional salvage chemotherapy due to advanced age or poor performance status, long-term administration is frequently limited by cumulative neurotoxicity. Herein, we present a case of successful BV monotherapy re-administration and extended treatment over 4.3 years in a vulnerable patient. This therapeutic approach expands treatment options available for elderly patients and those with poor performance status.